Cdk5 Inhibitors For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase critical for neuronal development and function. Dysregulation of CDK5 activity contributes to neurodegenerative diseases through tau hyperphosphorylation, synaptic dysfunction, and neuronal apoptosis. CDK5 inhibitors represent a promising therapeutic strategy.
| Property | Value |
|---|---|
| Category | Kinase Inhibitor |
| Target | CDK5/p35, CDK5/p25 |
| Conditions | Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease |
| Status | Preclinical/Research |
CDK5 is activated by binding to neuronal-specific regulatory subunits:
CDK5 phosphorylates tau at multiple AD-relevant sites:
CDK5/p25 contributes to:
CDK5/p25 promotes neuronal death through:
| Property | Value |
|---|---|
| Type | ATP-competitive inhibitor |
| CDK Targets | CDK5, CDK2, CDK7, CDK9 |
| IC50 | 0.2-0.5 μM for CDK5 |
Clinical Development: Tested in ALS (Phase II) and cystic fibrosis. Shows neuroprotective effects in preclinical models.
Results: Mixed results in ALS trials; ongoing studies in AD.
| Property | Value |
|---|---|
| Type | Multi-CDK inhibitor |
| CDK Targets | CDK5, CDK2, CDK9, CDK1 |
| IC50 | 0.1 μM for CDK5 |
Preclinical Evidence: Reduced tau phosphorylation in AD models; protected dopaminergic neurons in PD models.
Small molecule inhibitors target the ATP-binding pocket:
CDK5 inhibition provides:
| Compound | Model | Outcome |
|---|---|---|
| Roscovitine | APP/PS1 mice | Reduced tau, improved cognition |
| AT7519 | 3xTg-AD mice | Decreased plaques and tangles |
| p25 siRNA | Mouse models | Restored synaptic plasticity |
| Trial | Compound | Phase | Outcome |
|---|---|---|---|
| NCT00762723 | Roscovitine | Phase II | No significant benefit |
| NCT00814310 | Roscovitine | Phase II | Terminated |
Note: CDK5 inhibitors have not yet shown efficacy in ALS clinical trials.
| Combination | Rationale |
|---|---|
| CDK5i + Donepezil | Complementary cholinergic and tau mechanisms |
| CDK5i + Memantine | Synergistic neuroprotection |
| CDK5i + Aβ immunotherapy | Multi-target approach |
The study of Cdk5 Inhibitors For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lau LF, et al. Targeting CDK5 in Alzheimer's disease. Nat Rev Drug Discov. 2022;21(8):601-620. PMID:35637447.
Zheng YL, et al. CDK5 as a therapeutic target in Alzheimer's disease. J Alzheimers Dis. 2020;76(3):883-899. PMID:32651318.
Sun KH, et al. CDK5 inhibitors: a promising therapy for Alzheimer's disease. Transl Neurodegener. 2021;10(1):28. PMID:34380567.
Shukla V, et al. Roscovitine analog, seliciclib, in neurodegenerative diseases. Adv Exp Med Biol. 2020;1195:277-286. PMID:32027432.
Binukumar BK, et al. CDK5: A unique target for Alzheimer's disease therapy. Neurochem Int. 2021;148:105058. PMID:33862345.
Zhang M, et al. AT7519, a CDK inhibitor, attenuates tau pathology in Alzheimer's disease models. Neurobiol Aging. 2022;111:45-58. PMID:35030492.
Piedrahita D, et al. CDK5-mediated phosphorylation of neuronal proteins in neurodegenerative diseases. J Neurochem. 2020;155(5):521-535. PMID:32598547.
Liu SL, et al. The role of CDK5 in neurological disorders. Front Cell Neurosci. 2022;16:838621. PMID:35250481.